Peripheral Blood Expression of PD-L1 and PD-1 Associated With Tumor Immune Escape in Cutaneous Squamous Cell Carcinoma Patient
Yang Xueqi1, Li Dan2, Min Wei1
1. Department of Dermatology,The First Affiliated Hospital of Soochow University,Suzhou 215006,China; 2. Department of Dermatology,The Affiliated Hospital of Nanjing University Medical School,Nanjing 210009,China
Abstract：Objective To clarify the expression of PD-L1 in Cutaneous Squamous Cell Carcinoma（cSCC）,and discuss their possible roles in tumor immune escape.Methods First,we used immunohistochemistry method to examined the expression of PD-L1 molecule in age-matched normal subject samples,precancerous lesion samples and clinical skin cSCC tissue samples.And immunofluorescence was applied to detect the expression of PD-L1 in primary epithelial cells and skin squamous cell line A431.In addition,we also detected the expression of PD-L1 in the peripheral blood CD14 positive cells and PD -1 in peripheral T cells of cSCC patients by flow cytometry method,then analyzed the differences in PD-L1 expression levels in different populations.Results Immunohistochemical results showed a significant upregulation of PD-L1 in actinic keratinized tissues and squamous cell carcinoma tissues and a significant down-regulation of PD-L1 in normal skin tissues.Resultsof immunofluorescence showed a strongly difference of PD-L1 between primary epithelial cells and skin squamous cell.Furthermore,the increase of PD-L1 was no strongly associated with gender,age,and tumor risk factors.In addition（P>0.05）,the results also proved a significant high expression of co-inhibitory molecules such as PD-L1 in peripheral blood CD 14 positive cells and PD-L1 ligands PD-1 in peripheral T cells of cSCC.Conclusion Our results suggest that PD-L1 plays an important role in the occurrence of cSCC and the immune escape of tumors,and it provides the possibility for PD-L1 molecules to be used as a potential target for early diagnosis and immunotherapy of cSCC.
杨雪琪, 栗丹, 闵玮. 皮肤鳞状细胞癌患者外周血PD-L1和PD-1表达与肿瘤免疫逃逸相关[J]. 哈尔滨医药, 2023, 43(1): 5-8.
Yang Xueqi, Li Dan, Min Wei. Peripheral Blood Expression of PD-L1 and PD-1 Associated With Tumor Immune Escape in Cutaneous Squamous Cell Carcinoma Patient. journal1, 2023, 43(1): 5-8.
[1] Giovanna T.Analisi epidemiologica e caratterizzazione morfologica di pazienti affetti da tumore della cute non melanoma da registro nazionale[J].AIRTUM,2018,122(2):3-6 [2] Que SKT,Zwald FO,Schmults CD.Cutaneous squamous cell carcinoma:Incidence,risk factors,diagnosis,and staging[J].J Am Acad Dermatol,2018,78(2):237-247. [3] Migden MR,Rischin D,Schmults CD,et al.PD-1 Blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma[J].N Engl J Med,2018,379(4):341-351. [4] Soura E,Gagari E,Stratigos A.Advanced cutaneous squamous cell carcinoma:how is it defined and what new therapeutic approaches are available[J].CurrOpin Oncol,2019,31(5):461-468. [5] Curiel T.Blockade of PD-L1 improves myeloid dendritic cell-mediated antitumor immunity[J].Nat Med,2003,9(3):562-567. [6] Raez LE,Cassileth PA,Schlesselman JJ,et al.Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer[J].J Clin Oncol,2004,22(14):2800-2807. [7] Taube JM,Anders RA,Young GD,et al.Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape[J].Sci Transl Med,2012,4(127):12737. [8] Benson DM Jr,Bakan CE,Mishra A,et al.The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect:a therapeutic target for CT-011,a novel monoclonal anti-PD-1 antibody[J].Blood,2010,116(13):2286-2294. [9] Yoshinaga SK,Whoriskey JS,Khare SD,et al.T-cell co-stimulation through B7RP-1 and ICOS[J].Nature,1999,402(6763):827-832. [10] Latchman Y,Wood CR,Chernova T,et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J].Nature Immunology,2001,2(3):261. [11] Sica GL,Choi IH,Zhu G,et al.B7-H4,a molecule of the B7 family,negatively regulates T cell immunity[J].Immunity,2003,18(6):849-861. [12] Nakanishi J,Wada Y,Matsumoto K,et al.Overexpression of B7-H1(PD-L1)significantly associates with tumor grade and postoperative prognosis in human urothelial cancers[J].Cancer Immunol Immunother,2007,56(8):1173-1182. [13] Zhang G,Hou J,Shi J,et al.Soluble CD276(B7-H3)is released from monocytes,dendritic cells and activated T cells and is detectable in normal human serum[J].Immunology,2008,123(4):538-546. [14] Gadiot J.Overall survival and PD-L1 expression in metastasized malignant melanoma[J].Cancer,2011,117(3):2192-2201.
2023, Vol. 43 
